In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

This article was originally published in PharmAsia News

Executive Summary

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

You may also be interested in...



FDA Accepts Onyx’s Carfilzomib Application But Denies Priority Review

“Our plan is to continue our dialogue with the FDA and see if we can address their concerns and get the accelerated approval done,” Onyx R&D chief Love told analysts. The company completed its application to treat patients with refractory and relapsed multiple myeloma in September based on results of a single-arm study, a design the agency may not be inclined to accept.

Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision

The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC079373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel